Skip to contents
In This Issue:
Advancing its pioneering role in the emerging field of proteomics - the study of proteins - Partners Healthcare System (PHS) forged a comprehensive strategic alliance with Zyomyx, a leading biotechnology company responsible for creating the world's first fully functional protein chip platform. In collaboration with Zyomyx, PHS will apply leading technology in protein chips to facilitate a better understanding of the changing form and function of complex proteins. With a clearer picture of protein function, scientists will ultimately enhance their capabilities in early disease detection and disease progression.
“Zymoyx’ unique system gives our scientists the means to measure large numbers of proteins simultaneously,” said Samuel O. Thier, MD, Partners President and Chief Executive Officer. “Applying this tool to the broad scope of our basic and clinical research should speed the discovery and development of clinically relevant products and further our goal of better care for patients.”
The focus of the alliance, which was formally announced on June 24, is centered on the establishment of a protein profiling research facility. This facility will be dedicated to identifying and validating protein biomarkers – research that Partners’ scientists and physicians hope will provide another key to unlocking the codes to disease and ultimately, impact new therapies for patients.
The facility is scheduled to open at PHS’s research building at 65 Landsdowne Street in September. For more information about the new facility, email Chris Colecchi, Partners Research and Ventures (ccolecchi@partners.org).